FMP
Jan 26, 2025 7:00 PM - Danny Green(Last modified: Jan 27, 2025 9:04 AM)
Image credit: Google Images
Natera, Inc. (NASDAQ: NTRA) is a prominent player in the field of cell-free DNA and genetic testing. The company focuses on developing and commercializing molecular diagnostic tests that help in the early detection and management of various diseases, including cancer. Natera's competitors include companies like Illumina and Guardant Health, which also specialize in genetic testing and diagnostics.
Natera recently announced successful results from the Phase III CALGB (Alliance) / SWOG 80702 clinical trial in colorectal cancer. The trial, involving around 1,000 patients, showed that Signatera-positive patients experienced significant improvements in disease-free survival (DFS) and overall survival (OS) with the addition of celecoxib to standard chemotherapy. Specifically, the three-year DFS for these patients was 44.1%, compared to 26.6% for those not receiving celecoxib.
Dr. Alexey Aleshin, Natera's corporate chief medical officer, emphasized the importance of these findings in advancing personalized medicine for colorectal cancer patients. The study highlights Signatera's ability to predict the benefit of celecoxib, a well-tolerated therapy, in improving patient outcomes. This aligns with Natera's commitment to integrating personalized diagnostics into standard care to enhance health outcomes.
In addition to the CALGB trial, results from the ALTAIR clinical trial were presented. This trial explored treatment escalation with Trifluridine/Tipiracil (FTD/TPI) in colorectal cancer patients. Although it did not achieve statistical significance overall, it showed a significant benefit for resected oligometastatic stage IV patients treated with FTD/TPI. Signatera, a personalized molecular residual disease test, is designed to detect cancer recurrence earlier than standard tools, aiding in treatment decisions.
On the financial front, Natera's Chief Financial Officer, Brophy Michael Burkes, recently sold 687 shares of Common Stock at $171.80 each. Despite this sale, he still owns 109,733 shares. The stock is currently priced at $167.61, reflecting a decrease of 2.45%. NTRA has a market capitalization of approximately $22.13 billion, with a trading volume of 884,394 shares on the NASDAQ:NTRA exchange.
Sep 10, 2024 11:33 AM - Parth Sanghvi
When it comes to downloading historical stock data, Yahoo Finance has been a popular choice for many. However, for those looking for more comprehensive, accurate, and flexible options, Financial Modeling Prep (FMP) offers a suite of powerful tools and services that stand out as superior alternatives...
Nov 8, 2024 10:30 AM - Sanzhi Kobzhan
When it comes to investing in stocks, one of the key decisions an investor must make involves determining the intrinsic value of a company's shares. Equity valuation isn't just about numbers, it's an art mixed with science, aiming to predict future performance based on current and historical data. H...
Nov 22, 2024 10:08 AM - Parth Sanghvi
Fundamental analysis is one of the most essential tools for investors and analysts alike, helping them assess the intrinsic value of a stock, company, or even an entire market. It focuses on the financial health and economic position of a company, often using key data such as earnings, expenses, ass...